224 related articles for article (PubMed ID: 34713920)
1. Astrocytic VEGFA: An essential mediator in blood-brain-barrier disruption in Parkinson's disease.
Lan G; Wang P; Chan RB; Liu Z; Yu Z; Liu X; Yang Y; Zhang J
Glia; 2022 Feb; 70(2):337-353. PubMed ID: 34713920
[TBL] [Abstract][Full Text] [Related]
2. Erythrocytic α-synuclein contained in microvesicles regulates astrocytic glutamate homeostasis: a new perspective on Parkinson's disease pathogenesis.
Sheng L; Stewart T; Yang D; Thorland E; Soltys D; Aro P; Khrisat T; Xie Z; Li N; Liu Z; Tian C; Bercow M; Matsumoto J; Zabetian CP; Peskind E; Quinn JF; Shi M; Zhang J
Acta Neuropathol Commun; 2020 Jul; 8(1):102. PubMed ID: 32641150
[TBL] [Abstract][Full Text] [Related]
3. Astrocytic TYMP and VEGFA drive blood-brain barrier opening in inflammatory central nervous system lesions.
Chapouly C; Tadesse Argaw A; Horng S; Castro K; Zhang J; Asp L; Loo H; Laitman BM; Mariani JN; Straus Farber R; Zaslavsky E; Nudelman G; Raine CS; John GR
Brain; 2015 Jun; 138(Pt 6):1548-67. PubMed ID: 25805644
[TBL] [Abstract][Full Text] [Related]
4. Transfer of neuron-derived α-synuclein to astrocytes induces neuroinflammation and blood-brain barrier damage after methamphetamine exposure: Involving the regulation of nuclear receptor-associated protein 1.
Huang J; Ding J; Wang X; Gu C; He Y; Li Y; Fan H; Xie Q; Qi X; Wang Z; Qiu P
Brain Behav Immun; 2022 Nov; 106():247-261. PubMed ID: 36089218
[TBL] [Abstract][Full Text] [Related]
5. Transmission of α-synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson's disease?
Matsumoto J; Stewart T; Sheng L; Li N; Bullock K; Song N; Shi M; Banks WA; Zhang J
Acta Neuropathol Commun; 2017 Sep; 5(1):71. PubMed ID: 28903781
[TBL] [Abstract][Full Text] [Related]
6. Polarized α-synuclein trafficking and transcytosis across brain endothelial cells via Rab7-decorated carriers.
Alam P; Holst MR; Lauritsen L; Nielsen J; Nielsen SSE; Jensen PH; Brewer JR; Otzen DE; Nielsen MS
Fluids Barriers CNS; 2022 May; 19(1):37. PubMed ID: 35637478
[TBL] [Abstract][Full Text] [Related]
7. α-Synuclein oligomers potentiate neuroinflammatory NF-κB activity and induce Ca
Leandrou E; Chalatsa I; Anagnostou D; Machalia C; Semitekolou M; Filippa V; Makridakis M; Vlahou A; Anastasiadou E; Vekrellis K; Emmanouilidou E
Transl Neurodegener; 2024 Feb; 13(1):11. PubMed ID: 38378800
[TBL] [Abstract][Full Text] [Related]
8. Monomeric α-synuclein induces blood-brain barrier dysfunction through activated brain pericytes releasing inflammatory mediators in vitro.
Dohgu S; Takata F; Matsumoto J; Kimura I; Yamauchi A; Kataoka Y
Microvasc Res; 2019 Jul; 124():61-66. PubMed ID: 30885616
[TBL] [Abstract][Full Text] [Related]
9. Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease.
Argaw AT; Asp L; Zhang J; Navrazhina K; Pham T; Mariani JN; Mahase S; Dutta DJ; Seto J; Kramer EG; Ferrara N; Sofroniew MV; John GR
J Clin Invest; 2012 Jul; 122(7):2454-68. PubMed ID: 22653056
[TBL] [Abstract][Full Text] [Related]
10. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
[TBL] [Abstract][Full Text] [Related]
11. Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model.
Gan L; Vargas MR; Johnson DA; Johnson JA
J Neurosci; 2012 Dec; 32(49):17775-87. PubMed ID: 23223297
[TBL] [Abstract][Full Text] [Related]
12. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease.
Kelly LP; Carvey PM; Keshavarzian A; Shannon KM; Shaikh M; Bakay RA; Kordower JH
Mov Disord; 2014 Jul; 29(8):999-1009. PubMed ID: 24898698
[TBL] [Abstract][Full Text] [Related]
13. S-Nitrosylation of G protein-coupled receptor kinase 6 and Casein kinase 2 alpha modulates their kinase activity toward alpha-synuclein phosphorylation in an animal model of Parkinson's disease.
Wu W; Sung CC; Yu P; Li J; Chung KKK
PLoS One; 2020; 15(4):e0232019. PubMed ID: 32343709
[TBL] [Abstract][Full Text] [Related]
14. Human serum-derived α-synuclein auto-antibodies mediate NMDA receptor-dependent degeneration of CNS neurons.
Garg P; Würtz F; Hobbie F; Buttgereit K; Aich A; Leite K; Rehling P; Kügler S; Bähr M
J Neuroinflammation; 2024 Feb; 21(1):62. PubMed ID: 38419079
[TBL] [Abstract][Full Text] [Related]
15. α-Synuclein disrupts the anti-inflammatory role of Drd2 via interfering β-arrestin2-TAB1 interaction in astrocytes.
Du RH; Zhou Y; Xia ML; Lu M; Ding JH; Hu G
J Neuroinflammation; 2018 Sep; 15(1):258. PubMed ID: 30200997
[TBL] [Abstract][Full Text] [Related]
16. α-mangostin derivative 4e as a PDE4 inhibitor promote proteasomal degradation of alpha-synuclein in Parkinson's disease models through PKA activation.
Chen JY; Zhu Q; Cai CZ; Luo HB; Lu JH
Phytomedicine; 2022 Jul; 101():154125. PubMed ID: 35525236
[TBL] [Abstract][Full Text] [Related]
17. α-Synuclein-carrying astrocytic extracellular vesicles in Parkinson pathogenesis and diagnosis.
Wang P; Lan G; Xu B; Yu Z; Tian C; Lei X; Meissner WG; Feng T; Yang Y; Zhang J
Transl Neurodegener; 2023 Aug; 12(1):40. PubMed ID: 37620916
[TBL] [Abstract][Full Text] [Related]
18. The cervical lymph node contributes to peripheral inflammation related to Parkinson's disease.
Liu Z; Huang Y; Wang X; Li JY; Zhang C; Yang Y; Zhang J
J Neuroinflammation; 2023 Apr; 20(1):93. PubMed ID: 37038192
[TBL] [Abstract][Full Text] [Related]
19. Genetic deletion of nitric oxide synthase 2 ameliorates Parkinson's disease pathology and neuroinflammation in a transgenic mouse model of synucleinopathy.
Kim J; Han JY; Lee Y; Kim K; Choi YP; Chae S; Hoe HS
Mol Brain; 2023 Jan; 16(1):7. PubMed ID: 36647152
[TBL] [Abstract][Full Text] [Related]
20. Exosome-mediated delivery of antisense oligonucleotides targeting α-synuclein ameliorates the pathology in a mouse model of Parkinson's disease.
Yang J; Luo S; Zhang J; Yu T; Fu Z; Zheng Y; Xu X; Liu C; Fan M; Zhang Z
Neurobiol Dis; 2021 Jan; 148():105218. PubMed ID: 33296726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
